Rezpegaldesleukin: A Dual-Target Biologic for Atopic Dermatitis and Asthma

REZOLVE-AD Phase 2B shows that rezpegaldesleukin produced clinically meaningful benefits for both atopic dermatitis and asthma in a randomized induction cohort. For patients with comorbid atopic dermatitis and asthma, simultaneous improvement in both organ systems could simplify management and reduce overlapping inflammatory burden.

Dual‑indication biologics remain uncommon. The trial enrolled adults with moderate‑to‑severe atopic dermatitis, including a prespecified subgroup with asthma. In this randomized, double‑blind Phase 2B study, subcutaneous rezpegaldesleukin (24 μg/kg) was evaluated using skin endpoints (EASI, vIGA‑AD, NRS‑Itch) and a respiratory measure (ACQ‑5). These design elements strengthen confidence that the observed skin and airway effects are attributable to the drug.

Rezpegaldesleukin produced marked, clinically meaningful improvements in EASI, vIGA‑AD, and NRS‑Itch and was associated with reductions in ACQ‑5 scores among patients with asthma—directional outcomes that support dual‑target efficacy across skin and airway measures.

Rezpegaldesleukin expands regulatory T cells, providing a biologic rationale for concurrent benefit in both organ systems and for modulation of shared inflammatory pathways in atopic dermatitis and asthma.

These results most directly affect adults with moderate‑to‑severe atopic dermatitis who have comorbid asthma and will inform future trial design and real‑world evaluation. Investigators and clinicians may reasonably prioritize comparative studies and routine collection of ACQ‑5 in AD trials to better define clinical utility and to clarify how rezpegaldesleukin fits into treatment algorithms.

Key Takeaways:

• REZOLVE‑AD Phase 2B demonstrates rezpegaldesleukin’s potential to improve both atopic dermatitis and asthma outcomes.
• The probable mechanism—expansion of regulatory T cells—may underlie concurrent benefits across skin and airway inflammation.
• Future work should emphasize comparative effectiveness and incorporation of ACQ‑5 in dermatology trials to clarify clinical impact.